Digital healthcare product supplier Amalgam Rx has bought Avhana Health, a US-based clinical decision support (CDS) system producer backed by pharmaceutical firm GlaxoSmithKline, for an undisclosed amount.
Founded in 2014, Avhana provides software that leverages logged electronic health records to help medical professionals with clinical decision making. The product is used in 32 US states by a customer base of thousands of healthcare providers.
Amalgam Rx was founded in 2016 and provides patient support schemes, digital therapeutics and products combining digital and pharmaceutical interventions. It will merge its workflow optimisation tool with Avhana’s CDS platform in a bid to improve remote healthcare.
GlaxoSmithKline participated in a $750,000 seed round for Avhana in 2015 through its SR One unit, which was spun off as an independent venture capital firm in November 2020, investing with Boston Millennia Partners Founders Fund, DreamIt Health, Tedco TCF Fund and Wilmington Investor Network.
